Central neuromodulation for refractory pain.

Abstract

Chronic neuropathic pain affects 8.2% of adults, extrapolated to roughly 18 million people every year in the United States. Patients who have pain that cannot be controlled with pharmacologic management or less invasive techniques can be considered for deep brain stimulation or motor cortex stimulation. These techniques are not currently approved by the Food and Drug Administration for chronic pain and are, thus, considered off-label use of medical devices for this patient population. Conclusive effectiveness studies are still needed to demonstrate the best targets as well as the reliability of the results with these approaches.

• Authors: Nina Z Moore, Scott F Lempka, Andre Machado
• Journal: Neurosurgery clinics of North America (Neurosurg Clin N Am) Vol. 25 Issue 1 Pg. 77-83 (Jan 2014) ISSN: 1558-1349 [Electronic] United States
• PMID: 24262901 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Topics

• Deep Brain Stimulation
• Electric Stimulation Therapy
• Humans
• Motor Cortex (physiology)
• Pain, Intractable (therapy)
• Randomized Controlled Trials as Topic